^
    Back
    Association details:
    Biomarker:PD-L1 expression
    Cancer:Lung Non-Small Cell Squamous Cancer
    Drug:Libtayo (cemiplimab-rwlc) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    ASCO.org
    Title:

    Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.1

    Published date:
    04/06/2023
    Excerpt:
    For patients with SCC, PD-L1 TPS 0%-49% and PS 0-1, clinicians may offer cemiplimab plus chemotherapy…
    Secondary therapy:
    Chemotherapy
    DOI:
    10.1200/JCO.23.00282
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Non Small Cell Lung Cancer)
    New
    Title:

    LIBTAYO® (CEMIPLIMAB) IN COMBINATION WITH CHEMOTHERAPY APPROVED BY EUROPEAN COMMISSION FOR THE FIRST-LINE TREATMENT OF ADVANCED PD-L1 POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)

    Excerpt:
    Regeneron Pharmaceuticals...announced that the European Commission (EC) approved Libtayo® (cemiplimab) in combination with platinum-based chemotherapy for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with ≥1% PD-L1 expression. This includes patients that have no EGFR, ALK or ROS1 aberrations and whose tumors are metastatic or locally advanced and not candidates for definitive chemoradiation.
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer

    Excerpt:
    ...Part 1 only: Expression of PD-L1 in ...
    Trial ID:
    EMPOWER-Lung 3
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer

    Excerpt:
    ...Expression of PD-L1 in ≥50% of tumor cells determined by the commercially available assay performed by the central laboratory 4....
    Trial ID:
    EMPOWER-Lung 2
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer

    Excerpt:
    ...Biopsy evaluable for expression of PD-L1 as determined by a PD-L1 Immunohistochemistry (IHC) pharma diagnostic test (pharmDx) assay performed by a central laboratory 4....
    Trial ID:
    EMPOWER-lung 4